Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Revvity, Inc.
Revvity sells scientific instruments, chemicals, software, and diagnostic tests to research labs, biotech companies, and governments.
Revvity is a health-science tools company. If you work in a lab and need to measure something — how a drug affects cells, whether a newborn has a rare disease, whether a new molecule is safe — Revvity likely sells the machine, the chemical, or the test that does the measuring. Its customers are mostly the people who do science for a living: university and hospital labs, biotech and drug companies, and government health agencies.
The business splits into two broad halves. One half sells life-science tools: instruments and reagents, plus the software that runs them and organizes the data. The other half sells diagnostic testing platforms, the equipment and tests hospitals and labs use to check patients for disease, including newborn screening, where Revvity is a major player. The reagent business is the quiet engine — labs buy the same chemicals over and over, like printer ink, which makes revenue steadier than selling a big machine once. That recurring revenue is the appeal. A lab that buys an instrument keeps buying its consumables and software for years, and switching is painful once a workflow is built around a vendor. Revvity competes with much larger players such as Thermo Fisher Scientific and Danaher, who sell many of the same things, so scale and product breadth matter. Revvity's edge is depth in specific niches like newborn screening and certain research workflows rather than being the biggest generalist.
The company used to be PerkinElmer, a name with a long history in lab equipment. It sold off its big life-sciences-and-applied-solutions division to New Mountain Capital-backed buyers in 2023 and renamed itself Revvity, focusing on the tools-and-diagnostics core. That slimming-down story is the main thing to understand: a smaller, more focused company betting that steady lab spending and recurring reagent sales beat being a sprawling conglomerate.
Saved answer · last researched 12 Nov 2026